3-(3,4-dioxymethylenphenyl)-toxoflavin | 52199-05-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 3-(3,4-dioxymethylenphenyl)-toxoflavin
• 英文别名: 3-(3,4-Methylenedioxyphenyl)-toxoflavine；3-(3,4-Methylendioxyphenyl)toxoflavin；3-benzo[1,3]dioxol-5-yl-1,6-dimethyl-1H-pyrimido[5,4-e][1,2,4]triazine-5,7-dione；Pyrimido(5,4-e)-1,2,4-triazine-5,7(1H,6H)-dione, 3-(1,3-benzodioxol-5-yl)-1,6-dimethyl-；3-(1,3-benzodioxol-5-yl)-1,6-dimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione
• CAS: 52199-05-0
• 化学式: C₁₄H₁₁N₅O₄
• 分子量: 313.272
• InChiKey: FEQRWFABERLIOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  96.2
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Stat modulators
  申请人：Frank David A.

  公开号：US20110144043A1

  公开（公告）日：2011-06-16

  The present invention is directed to methods, kits and compositions for modulating the activity of Stat molecules (e.g., Stat1, Stat3 and Stat5). The compounds of the invention are useful for treating and/or preventing disorders characterized by Stat dysregulation, such as hyperproliferative disorders. Further, the compounds of the present invention are also useful in culturing stem cells and treating ischemic disorders.
• COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION
  申请人：Wong Chi-Huey

  公开号：US20130158037A1

  公开（公告）日：2013-06-20

  The present invention provides compounds which are potent inhibitors against Lpd activity, PDH activity, and/or the growth of tubercle bacillus , and thus are useful in the treatment of tuberculosis infection and associated conditions. The present invention is further directed to in vitro- and in vzivo-based methods of inhibiting Lpd and/or PDH activity. In certain embodiments, these methods are useful in inhibiting Lpd and/or PDH activity key to a pathogen's survival.
• COMPOSITIONS AND METHODS FOR DETECTING AND TREATING COLORECTAL CANCER
  申请人：The Regents of the University of Michigan

  公开号：US20150212088A1

  公开（公告）日：2015-07-30

  The present invention relates to compositions and methods for the detecting, treating, and empirically investigating the interaction between a subject's immune system and cancer stem cells. In particular, the present invention provides compositions and methods for using IL-22 cytokine signaling and/or downstream targets of IL-22 cytokine signaling (e.g., STAT3, DOT1L, SUZ12, EED) in the diagnosis, treatment, and empirical investigation of cancers characterized with cancer stem cells activated through IL-22 cytokine signaling.
• USE OF DIANHYDROGALACTITOL AND ANALOGS AND DERIVATIVES THEREOF, TOGETHER WITH RADIATION, TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND GLIOBLASTOMA MULTIFORME AND SUPPRESS PROLIFERATION OF CANCER STEM CELLS
  申请人：DelMar Pharmaceuticals, Inc.

  公开号：US20190015379A1

  公开（公告）日：2019-01-17

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and for the treatment of glioblastoma multiforme (GBM). Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.
• ENHANCED IMMUNOTHERAPY OF CANCER USING TARGETED TRANSCRIPTIONAL MODULATORS
  申请人：DANA-FARBER CANCER INSTITUTE, INC.

  公开号：US20200230135A1

  公开（公告）日：2020-07-23

  The present invention relates to a combination of a signal transducer and activator of transcription 3 (STAT3) activity inhibitor; and an immune checkpoint inhibitor for use in treating or preventing the hyperproliferative disorder in a subject. Preferably, the STA3 activity inhibitor is pyrimethamine or atovaquone, and the immune checkpoint inhibitor is an anti-PD1 antibody. Preferably, the hyperproliferative disorder is a glioma or a glioblastoma.